Remdesivir (GS-5734)
€0.00
In stock
SKU
EMC02654
Catalog Number: EMC02654
Size: 25 mg, 50 mg, 100 mg
CAS Number: 1809249-37-3
Category: API's & Drug Standards, Cancer Research and Antivirals
Request info Remdesivir (GS-5734)
Size: 25 mg, 50 mg, 100 mg
CAS Number: 1809249-37-3
Category: API's & Drug Standards, Cancer Research and Antivirals
Request info Remdesivir (GS-5734)
Remdesivir (development code GS-5734) is an antiviral drug, a novel nucleotide analogue prodrug. It was developed by Gilead sciences as a treatment for Ebola virus disease and Marburg virus infections, though it has subsequently also been found to show reasonable antiviral activity against more distantly related viruses such as respiratory syncytial virus, Junin virus, Lassa fever virus and MERS-coronavirus. There is possible activity against other coronaviruses such as SARS and potentially 2019-nCoV infections.
February update : Although remdesivir is not a licensed or approved drug anywhere in the world at present time, treatment has shown activity against other coronaviruses such as severe acute respiratory syndrome (SARS) in animal models. Gilead Sciences has announced collaboration with Chinese, US, and global health officials in order to investigate the safety and efficacy of its investigational antiviral compound remdesivir (GS-5734) against the novel coronavirus (2019-nCoV). Gilead is working with Chinese health authorities to establish a randomized, controlled clinical trial.
February 5th update : The Wuhan Institute of Virology has said that an application has been filed seeking a new patent on Gilead Sciences’ investigational antiviral drug, remdesivir, believed to have the potential to treat the new coronavirus. China’s state-owned Xinhua news agency reported that Friendship Hospital plans to study a total of 761 patients in two trials-one trial to assess 308 with mild or moderate infection, the other 453 severely infected patients-at Jinyintan Hospital in Wuhan, under Phase III studies that have been officially launched.
Product Details
Formula: C27H35N6O8P
Molecular Weight: 605.28
Purity: Min 98%
Appearance : Light yellow to yellow powder
Storage Conditions: -18 deg C
February update : Although remdesivir is not a licensed or approved drug anywhere in the world at present time, treatment has shown activity against other coronaviruses such as severe acute respiratory syndrome (SARS) in animal models. Gilead Sciences has announced collaboration with Chinese, US, and global health officials in order to investigate the safety and efficacy of its investigational antiviral compound remdesivir (GS-5734) against the novel coronavirus (2019-nCoV). Gilead is working with Chinese health authorities to establish a randomized, controlled clinical trial.
February 5th update : The Wuhan Institute of Virology has said that an application has been filed seeking a new patent on Gilead Sciences’ investigational antiviral drug, remdesivir, believed to have the potential to treat the new coronavirus. China’s state-owned Xinhua news agency reported that Friendship Hospital plans to study a total of 761 patients in two trials-one trial to assess 308 with mild or moderate infection, the other 453 severely infected patients-at Jinyintan Hospital in Wuhan, under Phase III studies that have been officially launched.
Product Details
Formula: C27H35N6O8P
Molecular Weight: 605.28
Purity: Min 98%
Appearance : Light yellow to yellow powder
Storage Conditions: -18 deg C
| Is Featured? | No |
|---|
Write Your Own Review